Vitreous levels of erythropoietin in patients with macular oedema secondary to retinal vein occlusions: a comparative study with diabetic macular oedema (vol 23, pg 1066, 2009)

被引：0
|
作者：
Garcia-Arumi, J.
Fonollosa, A.
Macia, C.
Hernandez, C.
Martinez-Castillo, V.
Boixadera, A.
Zapata, M. A.
Simo, R.
机构：
来源：
EYE | 2009年 / 23卷 / 08期
关键词：
D O I：
10.1038/eye.2009.128
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
Correction to: Eye (2009) 23, 1066–1071; doi:10.1038/eye.2008.230; published online 1 August 2008 The author name J García-Arumí was published incorrectly in the above referenced paper. The correct author list is shown above. The authors would like to apologize for this error.
引用
收藏
页码：1754 / 1754
页数：1
相关论文
共 50 条
  • [21] Long-term outcomes for patients treated for macular oedema secondary to retinal vein occlusion: a systematic review
    Hunter, Alexandra
    Williams, Michael
    BMJ OPEN OPHTHALMOLOGY, 2022, 7 (01):
  • [22] Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab
    T D Papakostas
    L Lim
    T van Zyl
    J B Miller
    B S Modjtahedi
    C M Andreoli
    D Wu
    L H Young
    I K Kim
    D G Vavvas
    D D Esmaili
    D Husain
    D Eliott
    L A Kim
    Eye, 2016, 30 : 79 - 84
  • [23] Impact of initial visual acuity on anti-VEGF treatment outcomes in patients with macular oedema secondary to retinal vein occlusions in routine clinical practice
    Wai, Karen M.
    Khan, Mehnaz
    Srivastava, Sunil
    Rachitskaya, Aleksandra
    Silva, Fabiana Q.
    Deasy, Ryan
    Schachat, Andrew P.
    Babiuch, Amy
    Ehlers, Justis P.
    Kaiser, Peter K.
    Yuan, Alex
    Singh, Rishi P.
    BRITISH JOURNAL OF OPHTHALMOLOGY, 2017, 101 (05) : 574 - 579
  • [24] Intravitreal Aflibercept (Eylea®): A Review of Its Use in Patients with Macular Oedema Secondary to Central Retinal Vein Occlusion
    Yang, Lily P. H.
    McKeage, Kate
    DRUGS & AGING, 2014, 31 (05) : 395 - 404
  • [25] Intravitreal Aflibercept (Eylea®): A Review of Its Use in Patients with Macular Oedema Secondary to Central Retinal Vein Occlusion
    Lily P. H. Yang
    Kate McKeage
    Drugs & Aging, 2014, 31 : 395 - 404
  • [26] Intravitreal aflibercept for macular oedema secondary to central retinal vein occlusion in patients with prior treatment with bevacizumab or ranibizumab
    Papakostas, T. D.
    Lim, L.
    van Zyl, T.
    Miller, J. B.
    Modjtahedi, B. S.
    Andreoli, C. M.
    Wu, D.
    Young, L. H.
    Kim, I. K.
    Vavvas, D. G.
    Esmaili, D. D.
    Husain, D.
    Eliott, D.
    Kim, L. A.
    EYE, 2016, 30 (01) : 79 - 84
  • [27] Outcomes of switching treatment to aflibercept in patients with macular oedema secondary to central retinal vein occlusion refractory to ranibizumab
    Vasileios Konidaris
    Zahra Al-Hubeshy
    Konstantinos T. Tsaousis
    Konstantina Gorgoli
    Somnath Banerjee
    Theodoros Empeslidis
    International Ophthalmology, 2018, 38 : 207 - 213
  • [28] Current Outcomes of Anti-VEGF Therapy in the Treatment of Macular Oedema Secondary to Branch Retinal Vein Occlusions: A Meta-Analysis
    Spooner, Kimberly
    Hong, Thomas
    Fraser-Bell, Samantha
    Chang, Andrew A.
    OPHTHALMOLOGICA, 2019, 242 (03) : 163 - 177
  • [29] Prospective study of aflibercept for the treatment of persistent macular oedema secondary to retinal vein occlusions in eyes not responsive to long-term treatment with bevacizumab or ranibizumab
    Spooner, Kimberly
    Fraser-Bell, Samantha
    Hong, Thomas
    Chang, Andrew
    CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2020, 48 (01): : 53 - 60
  • [30] Retrospective, Observational Study in Patients Receiving a Dexamethasone Intravitreal Implant 0.7 mg for Macular Oedema Secondary to Retinal Vein Occlusion
    Augustin, Albert J.
    Holz, Frank G.
    Haritoglou, Christos
    Mayer, Wolfgang J.
    Bopp, Silvia
    Scheuerle, Alexander F.
    Maier, Matthias
    Sekundo, Walter
    Sandner, Dirk
    Shirlaw, Andrew
    Hattenbach, Lars-Olof
    OPHTHALMOLOGICA, 2015, 233 (01) : 18 - 26
12345